Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Understanding how tumors respond to radiation has been a lifelong process for Puneeth Iyengar, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center. He began testing theories in school science fairs as an adolescent growing up in Louisiana. Studying at MIT furthered his interest in the biologic and engineering aspects of medicine, and he earned a bachelor of science degree in biology before receiving his M.D./Ph.D. degrees from Albert Einstein College of Medicine in New York in 2005.
Lung Cancer Video Library 2025
AlexandraGBeneke
As part of the 2025 Lung Cancer Video Library, where oncologists discuss the most emerging treatment options and informatIon in lung cancer, Dr. Puneeth Iyengar (Memorial Sloan Kettering Cancer Center) discusses when to consider radiation and/or surgery in the management of advanced non-small cell lung cancer (NSCLC) for survival benefit.
Image
In these video series, Dr. Iyengar discusses two indications, or timepoints, where radiation and/or surgery may be used to improve the survival outcomes in metastatic, non-small cell lung cancer (NSCLC) patients, specifically focusing on consolidation. He discusses various trials, but also the importance of how radiation would help patients who were receiving immunotherapy-based regiments. This led to the discussion of NRG-LU002, a randomized phase II/III trial of maintenance systemic therapy vs. local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).
He also discusses how biology affects non-small cell lung cancer (NSCLC) outcomes, the results of NRG-LU002, a randomized phase II/III trial of maintenance systemic therapy vs. local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC), and how to select patients for the optimal therapy for metastatic non-small cell lung cancer (NSCLC).
To watch the complete playlist, click here.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention.
To watch the complete playlist, click here.
Thanks to Regeneron and Daiichi-Sankyo.
Online Community
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...